Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Active not recruiting 4Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 7Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 66Neoplasm Metastasis 14Brain Neoplasms 10Neoplasms 9Endometrial Neoplasms 9Prostatic Neoplasms 7Glioblastoma 7Ovarian Neoplasms 6Triple Negative Breast Neoplasms 5Glioma 5Sarcoma 4Recurrence 3Neoplasms by Site 3Meningioma 3Carcinoma, Non-Small-Cell Lung 3Breast Diseases 3Unilateral Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Osteosarcoma 2Liposarcoma 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Ependymoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Advanced Breast Cancer 2Venous Thromboembolism 1Uterine Cervical Neoplasms 1

Interventions

enzalutamide 92Magnetic Resonance Spectroscopy 87Specimen Handling 66Prednisone 65Androgen Antagonists 59Abiraterone Acetate 59apalutamide 56Radiosurgery 53Radiotherapy 47Leuprolide 47darolutamide 46abiraterone 44Docetaxel 43Radiation 31Pluvicto 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Biopsy 30relugolix 28Surveys and Questionnaires 28pembrolizumab 26gallium 68 PSMA-11 26Standard of Care 26Triptorelin Pamoate 25Goserelin 25bicalutamide 23Gonadotropin-Releasing Hormone 23Brachytherapy 21Carboplatin 20X-Rays 19luprolide acetate gel depot 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Prostatic Neoplasms × abemaciclib × 1 year × Clear all
NCT06630325 2026-04-28

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
6 enrolled 3 charts
GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03706365 2026-04-24

CYCLONE 2

Eli Lilly and Company

Phase 2/3 Active not recruiting
393 enrolled 23 charts
Genitourinary

Prostatic Neoplasms

NCT05113537 2026-04-13

UPLIFT

University of California, San Francisco

Phase 1/2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT05999968 2026-03-05

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Eli Lilly and Company

Phase 1 Completed
10 enrolled
Genitourinary

Prostatic Neoplasms

NCT05617885 2026-02-27

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
9 enrolled
Genitourinary

Prostatic Neoplasms

NCT04751929 2026-02-20

Abemaciclib With or Without Atezolizumab for mCRPC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

Eli Lilly and Company

Phase 3 Active not recruiting
925 enrolled 12 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡